Literature DB >> 25196658

Increasing use of observation among men at low risk for prostate cancer mortality.

Chad R Ritch1, Amy J Graves2, Kirk A Keegan3, Shenghua Ni4, Jeffrey C Bassett2, Sam S Chang5, Matthew J Resnick2, David F Penson2, Daniel A Barocas2.   

Abstract

PURPOSE: There are growing concerns regarding the overtreatment of localized prostate cancer. It is also relatively unknown whether there has been increased uptake of observational strategies for disease management. We assessed the temporal trend in observation of clinically localized prostate cancer, particularly in men with low risk disease, who were young and healthy enough to undergo treatment.
MATERIALS AND METHODS: We performed a retrospective cohort study using the SEER-Medicare database in 66,499 men with localized prostate cancer between 2004 and 2009. The main study outcome was observation within 1 year after diagnosis. We performed multivariable analysis to develop a predictive model of observation adjusting for diagnosis year, age, risk and comorbidity.
RESULTS: Observation was performed in 12,007 men (18%) with a slight increase with time from 17% to 20%. However, there was marked increase in observation from 18% in 2004 to 29% in 2009 in men with low risk disease. Men 66 to 69 years old with low risk disease and no comorbidities had twice the odds of undergoing observation in 2009 vs 2004 (OR 2.12, 95% CI 1.73-2.59). Age, risk group, comorbidity and race were independent predictors of observation (each p <0.001), in addition to diagnosis year.
CONCLUSIONS: We identified increasing use of observation for low risk prostate cancer between 2004 and 2009 even in men young and healthy enough for treatment. This suggests growing acceptance of surveillance in this group of patients.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  age groups; comorbidity; continental population groups; prostatic neoplasms; therapy

Mesh:

Year:  2014        PMID: 25196658      PMCID: PMC4363002          DOI: 10.1016/j.juro.2014.08.102

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

1.  Guideline for the management of clinically localized prostate cancer: 2007 update.

Authors:  Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

2.  Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.

Authors:  Steven B Zeliadt; Arnold L Potosky; Ruth Etzioni; Scott D Ramsey; David F Penson
Journal:  Urology       Date:  2004-12       Impact factor: 2.649

3.  20-year outcomes following conservative management of clinically localized prostate cancer.

Authors:  Peter C Albertsen; James A Hanley; Judith Fine
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

4.  What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.

Authors:  Daniel A Barocas; Janet E Cowan; Joseph A Smith; Peter R Carroll
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

5.  Outcomes of localized prostate cancer following conservative management.

Authors:  Grace L Lu-Yao; Peter C Albertsen; Dirk F Moore; Weichung Shih; Yong Lin; Robert S DiPaola; Michael J Barry; Anthony Zietman; Michael O'Leary; Elizabeth Walker-Corkery; Siu-Long Yao
Journal:  JAMA       Date:  2009-09-16       Impact factor: 56.272

6.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

7.  Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.

Authors:  Susan R Harlan; Matthew R Cooperberg; Eric P Elkin; Deborah P Lubeck; Maxwell V Meng; Shilpa S Mehta; Peter R Carroll
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

8.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Authors:  Laurence Klotz; Liying Zhang; Adam Lam; Robert Nam; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

9.  Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study.

Authors:  Richard M Hoffman; Linda C Harlan; Carrie N Klabunde; Frank D Gilliland; Robert A Stephenson; William C Hunt; Arnold L Potosky
Journal:  J Gen Intern Med       Date:  2003-10       Impact factor: 5.128

10.  The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.

Authors:  Matthew R Cooperberg; Deborah P Lubeck; Maxwell V Meng; Shilpa S Mehta; Peter R Carroll
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

View more
  14 in total

1.  Toward ethically responsible choice architecture in prostate cancer treatment decision-making.

Authors:  J S Blumenthal-Barby; Denise Lee; Robert J Volk
Journal:  CA Cancer J Clin       Date:  2015-05-21       Impact factor: 508.702

2.  More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades.

Authors:  J B Eifler; J Alvarez; T Koyama; R M Conwill; C R Ritch; K E Hoffman; M J Resnick; D F Penson; D A Barocas
Journal:  J Urol       Date:  2016-10-27       Impact factor: 7.450

3.  Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study.

Authors:  Ronald E Myers; Amy E Leader; Jean Hoffman Censits; Edouard J Trabulsi; Scott W Keith; Anett M Petrich; Anna M Quinn; Robert B Den; Mark D Hurwitz; Costas D Lallas; Sarah E Hegarty; Adam P Dicker; Charnita M Zeigler-Johnson; Veda N Giri; Hasan Ayaz; Leonard G Gomella
Journal:  J Cancer Educ       Date:  2018-02       Impact factor: 2.037

4.  Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer.

Authors:  Richard M Hoffman; Tania Lobo; Stephen K Van Den Eeden; Kimberly M Davis; George Luta; Amethyst D Leimpeter; David Aaronson; David F Penson; Kathryn Taylor
Journal:  Med Decis Making       Date:  2019-10-21       Impact factor: 2.583

5.  Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations.

Authors:  Parth K Modi; Samuel R Kaufman; Tudor Borza; Phyllis Yan; David C Miller; Ted A Skolarus; John M Hollingsworth; Edward C Norton; Vahakn B Shahinian; Brent K Hollenbeck
Journal:  Cancer       Date:  2018-06-15       Impact factor: 6.860

6.  The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort.

Authors:  Maximilian F Lang; Mark D Tyson; JoAnn Rudd Alvarez; Tatsuki Koyama; Karen E Hoffman; Matthew J Resnick; Matthew R Cooperberg; Xiao-Cheng Wu; Vivien Chen; Lisa E Paddock; Ann S Hamilton; Mia Hashibe; Michael Goodman; Sheldon Greenfield; Sherrie H Kaplan; Antoinette Stroup; David F Penson; Daniel A Barocas
Journal:  Urology       Date:  2017-02-09       Impact factor: 2.649

7.  A hospital-based study of initial observation for low-risk prostate cancer and its predictors in the United States.

Authors:  Matthew J Maurice; Hui Zhu; Robert Abouassaly
Journal:  Can Urol Assoc J       Date:  2015-04-13       Impact factor: 1.862

8.  Robots drive the German radical prostatectomy market: a total population analysis from 2006 to 2013.

Authors:  C Groeben; R Koch; M Baunacke; M P Wirth; J Huber
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-08-23       Impact factor: 5.554

9.  Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer.

Authors:  Kathryn L Taylor; Richard M Hoffman; Kimberly M Davis; George Luta; Amethyst Leimpeter; Tania Lobo; Scott P Kelly; Jun Shan; David Aaronson; Catherine A Tomko; Amy J Starosta; Charlotte J Hagerman; Stephen K Van Den Eeden
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-06-02       Impact factor: 4.254

10.  Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study.

Authors:  Richard M Hoffman; Sarah L Mott; Bradley D McDowell; Sonia T Anand; Kenneth G Nepple
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-06-09       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.